scholarly journals Role of vascular endothelial growth factor in the pathogenesis of hepatic steatosis and dyslipidemia

2020 ◽  
pp. 31-36
Author(s):  
И.Л. Гуляева ◽  
И.А. Булатова ◽  
Л.Д. Пестренин
Keyword(s):  
Metabolic Syndrome ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Low Density Lipoproteins ◽  
Control Group ◽  
Low Density ◽  
Very Low Density Lipoproteins ◽  
Fatty Liver Index ◽  
Nonalcoholic Hepatic Steatosis ◽  
Hepatic Steatosis Index

Цель исследования - изучение роли васкулоэндотелиального фактора роста в патогенезе неалкогольного стеатоза печени и дислипидемии при метаболическом синдроме. Методика. Обследовано 35 пациентов с неалкогольным стеатозом печени, в том числе 22 женщины и 13 мужчин. Группу контроля составили 12 сопоставимых по полу и возрасту лиц без патологии печени и признаков метаболического синдрома. Наличие жирового гепатоза подтверждали методом ультразвукового исследования. У пациентов с патологией печени рассчитывали индексы-предикторы стеатоза: Fatty Liver Index (FLI) и Hepatic Steatosis Index (HSI). У всех участников исследования определяли уровни провоспалительных цитокинов и васкулоэндотелиального фактора роста (ВЭФР), оценивали также липидный спектр крови и функциональные печеночные пробы. Результаты. У пациентов со стеатозом печени наблюдалось значимое увеличение уровней провоспалительных цитокинов, ВЭФР, общего холестерина и липопротеинов низкой и очень низкой плотности. Индекс атерогенности также был значимо выше, чем в контрольной группе. Концентрация ВЭФР положительно коррелировала с показателями окружности талии, тимоловой пробы, уровнями общего холестерина, липопротеинов низкой плотности и индексом атерогенности. Чувствительность FLI составила 91,4%, HSI - 97,1%. При этом, значения FLI и HSI значимо коррелировали с уровнем ВЭФР. Заключение. Полученные данные позволяют предположить, что ВЭФР, один из основных маркеров эндотелиальной дисфункции, может играть немаловажную роль в патогенезе неалкогольного стеатоза печени и дислипидемии у пациентов с метаболическомим синдромом The aim of the study was to assess the role of vascular endothelial growth factor (VEGF) in the pathogenesis of nonalcoholic hepatic steatosis and dyslipidemia in patients with signs of metabolic syndrome. Methods. 35 patients with nonalcoholic fatty liver disease, including 22 women and 13 men, were evaluated. The sex- and age-matched control group consisted of 12 people without liver pathology and metabolic syndrome criteria. Presence of hepatic steatosis was confirmed by an ultrasound examination. The Fatty Liver Index (FLI) and the Hepatic Steatosis Index (HSI) were calculated for patients with hepatic steatosis. Concentrations of proinflammatory cytokines and VEGF were measured for all participants. Also, blood biochemistry, including the lipid profile and liver function tests, was analyzed. Results. In patients with hepatic steatosis, levels of proinflammatory cytokines and VEGF were significantly increased. Also, concentrations of total cholesterol, low-density lipoproteins, and very low-density lipoproteins were higher in patients with the liver pathology than in the control group. Atherogenic coefficient was increased in hepatic steatosis. Significant correlations were observed between VEGF and waist circumference, thymol test, total cholesterol, low-density lipoproteins, very low-density lipoproteins, and atherogenic coefficient. Sensitivity of FLI and HIS was 91.4% and 97.1%, respectively. Also, FLI significantly correlated with HSI and VEGF level. Conclusion. The study suggested that VEGF, of the main markers of endothelial dysfunction, plays an important role in the pathogenesis of nonalcoholic hepatic steatosis and dyslipidemia in patients with signs of metabolic syndrome.

scholarly journals Reactivity features of cytokines and vasculoendothelial growth factor in patients with chronic cerebral ischemia and metabolic syndrome

2019 ◽  
Keyword(s):  
Metabolic Syndrome ◽  
Cerebral Ischemia ◽  
Growth Factor ◽  
Waist Circumference ◽  
Interleukin 6 ◽  
Interleukin 10 ◽  
Low Density Lipoproteins ◽  
Low Density ◽  
Chronic Cerebral Ischemia ◽  
Very Low Density Lipoproteins

The purpose of the research is to determine the correlation between cytokines (interleukin-6, interleukin-10), vasculoendothelial growth factor, biochemical and anthropometric parameters in patients with chronic cerebral ischemia and metabolic syndrome. We examined 77 patients with chronic cerebral ischemia divided into 2 groups: with metabolic syndrome and without metabolic syndrome. In addition to neuroimaging, anthropometric and biochemical research we determined serum concentrations of interleukin-6, interleukin-10 and vasculoendothelial growth factor. It was found that patients with chronic cerebral ischemia and metabolic syndrome had significantly higher concentrations of interleukin-6, vasculoendothelial growth factor, indicators of weight, body mass index, waist circumference, glucose concentration, triglycerides, very low density lipoproteins, and high density lipoproteins was lower compared with the group without metabolic syndrome. During the comparing process of the biomarkers concentrations depending on gender, it was found that in patients with chronic cerebral ischemia and metabolic syndrome, the concentration of interleukin-6 was significantly higher in women than in men. Examination of all patients with chronic cerebral ischemia showed a direct correlation between the concentrations of interleukin-6 and glucose, the concentrations of interleukin-6 and weight, the concentrations of interleukin-6 and the waist circumference and between the concentration of vasculoendothelial growth factor and the waist circumference, in the group with metabolic syndrome - between the concentrations of interleukin-6 and interleukin-10, and in the group without metabolic syndrome - between the waist circumference and the atherogenic coefficient, between the concentrations of low density lipoproteins and β-lipoproteids, between the concentrations of low density lipoproteins and very low density lipoproteins. Thereby, metabolic syndrome is an additional complicating factor that comprehensively affects the reactivity of cytokines and vasculoendothelial growth factor in the pathogenesis of chronic cerebral ischemia.

scholarly journals Diagnostic accuracy and limitations of non-invasive tests in patients with metabolic-associated fatty liver disease

2021 ◽  
Vol 44 (5) ◽  
pp. 168-172
Author(s):  
Y Sánchez Torrijos ◽  
A Lucena Valera ◽  
J Ampuero Herrojo
Keyword(s):  
Liver Disease ◽  
Diagnostic Accuracy ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Fibrosis Score ◽  
Non Invasive ◽  
Fatty Liver Index ◽  
Nafld Fibrosis Score ◽  
Hepatic Steatosis Index

Resumen La incidencia de la enfermedad del hígado graso asociada al metabolismo (MAFLD) ha aumentado en los últimos años debido al estilo de vida actual. La biopsia de hígado sigue siendo la herramienta estándar de oro para detectar y estadificar MAFLD. Por otro lado, se están desarrollando múltiples biomarcadores y pruebas no invasivas para superar las limitaciones de la biopsia hepática, incluidos el costo y la invasividad. Las pruebas no invasivas se centran principalmente en la esteatosis y, en particular, en la fibrosis hepática y se pueden clasificar en pruebas patentadas y no patentadas. Si bien hepatic steatosis index y fatty liver index son las pruebas más comunes utilizadas para la detección de esteatosis, Hepamet Fibrosis Score, NAFLD fibrosis score, FIB-4, OWLiver®, y ELF® son las más utilizadas para la fibrosis hepática. Sin embargo, las pruebas no invasivas también tienen limitaciones que conviene resaltar ya que sus resultados podrían verse afectados por la presencia de diabetes, obesidad o por edades extremas que podrían dar lugar a falsos positivos o negativos. Para maximizar la precisión de los tests no invasivos, se han propuesto diferentes combinaciones integradas en algoritmos escalonados. Esta revisión tiene como objetivo destacar las fortalezas y limitaciones de dichos tests para detectar y estadificar MAFLD.

scholarly journals Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome

2020 ◽  
Vol 2020 ◽  
pp. 1-7 ◽  
Author(s):  
Hande Erman ◽  
Engin Beydogan ◽  
Seher Irem Cetin ◽  
Banu Boyuk
Keyword(s):  
Metabolic Syndrome ◽  
Fatty Liver ◽  
Liver Steatosis ◽  
Cutoff Point ◽  
Healthy Controls ◽  
Roc Curve Analysis ◽  
Cross Sectional ◽  
Nonalcoholic Fatty Liver ◽  
Fatty Liver Index ◽  
Hepatic Steatosis Index

Background. Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, which has recently been mentioned as an independent cardiovascular risk factor. Objectives. Endocan is a novel molecule of endothelial dysfunction. We aimed to evaluate the associations of serum endocan levels with the hepatic steatosis index (HSI), fatty liver index (FLI), and degrees of hepatosteatosis in patients with metabolic syndrome with NAFLD. Design and Setting. This cross-sectional prospective study was performed in the outpatient clinic of an internal medicine department. Methods. The study included 40 patients with metabolic syndrome with NAFLD as noted using hepatic ultrasound and 20 healthy controls. Secondary causes of fatty liver were excluded. FLI and HSI calculations were recorded. Serum endocan level values were obtained after overnight fasting. Results. Higher values of HSI and FLI were found in the NAFLD groups than in the control groups (p<0.001). Five (12.5%) of 20 patients with liver steatosis had grade 1 liver steatosis, 15 (37.5%) patients had grade 2 liver steatosis, and 20 (50%) patients had grade 3 liver steatosis. Serum endocan levels were lower in patients with NAFLD compared with the healthy controls (146.56±133.29 pg/mL vs. 433.71±298.01 pg/mL, p<0.001). ROC curve analysis suggested that the optimum endocan value cutoff point for NAFLD was 122.583 pg/mL (sensitivity: 71.79%, specificity: 90%, PPV: 93.3%, and NPV: 62.1%). Conclusion. Serum endocan concentrations are low in patients with NAFLD, and the optimum cutoff point is 122.583 pg/mL. HSI and FLI were higher in patients with NAFLD; however, there was no correlation with serum endocan.

scholarly journals Very Low-Density Lipoproteins of Metabolic Syndrome Modulates STIM1, Suppresses Store-Operated Calcium Entry, and Deranges Myofilament Proteins in Atrial Myocytes

2019 ◽  
Vol 8 (6) ◽  
pp. 881 ◽  
Author(s):  
Yi-Lin Shiou ◽  
Hsin-Ting Lin ◽  
Liang-Yin Ke ◽  
Bin-Nan Wu ◽  
Shyi-Jang Shin ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Metabolic Syndrome ◽  
Calcium Release ◽  
Nuclear Translocation ◽  
Low Density Lipoproteins ◽  
Low Density ◽  
Atrial Myocytes ◽  
Very Low Density Lipoproteins ◽  
Activated T Cells

Individuals with metabolic syndrome (MetS) are at high risk for atrial myopathy and atrial fibrillation. Very low-density lipoproteins (VLDLs) of MetS (MetS-VLDLs) are cytotoxic to atrial myocytes in vivo and in vitro. The calcineurin–nuclear factor of activated T-cells (NFAT) pathway, which is regulated by stromal interaction molecule 1 (STIM1)/ calcium release-activated calcium channel protein 1 (Orai1)–mediated store-operated Ca2+ entry (SOCE), is a pivotal mediator of adaptive cardiac hypertrophy. We hypothesized that MetS-VLDLs could affect SOCE and the calcineurin–NFAT pathway. Normal-VLDL and MetS-VLDL samples were isolated from the peripheral blood of healthy volunteers and individuals with MetS. VLDLs were applied to HL-1 atrial myocytes for 18 h and were also injected into wild-type C57BL/6 male mouse tails three times per week for six weeks. After the sarcoplasmic reticulum (SR) Ca2+ store was depleted, SOCE was triggered upon reperfusion with 1.8 mM of Ca2+. SOCE was attenuated by MetS-VLDLs, along with reduced transcriptional and membranous expression of STIM1 (P = 0.025), and enhanced modification of O-GlcNAcylation on STIM1 protein, while Orai1 was unaltered. The nuclear translocation and activity of calcineurin were both reduced (P < 0.05), along with the alteration of myofilament proteins in atrial tissues. These changes were absent in normal-VLDL-treated cells. Our results demonstrated that MetS-VLDLs suppressed SOCE by modulating STIM1 at the transcriptional, translational, and post-translational levels, resulting in the inhibition of the calcineurin–NFAT pathway, which resulted in the alteration of myofilament protein expression and sarcomere derangement in atrial tissues. These findings may help explain atrial myopathy in MetS. We suggest a therapeutic target on VLDLs to prevent atrial fibrillation, especially for individuals with MetS.

The therapeutic effect of some drugs and vegetable juices on the lipid profiles in male rabbits induced atherosclerosis.

2019 ◽  
Vol 9 (o3) ◽  
Author(s):  
Sawsan Taha Ahmed al-Haddad ◽  
Zaid Mohammed Mubarak Almahdawi ◽  
Munife S. Ahmed Al-janabi
Keyword(s):  
Green Tea ◽  
Density Lipoprotein ◽  
Lemon Juice ◽  
Low Density Lipoproteins ◽  
High Density ◽  
High Density Lipoproteins ◽  
Control Group ◽  
Low Density ◽  
Very Low Density Lipoproteins ◽  
Group 5

This study was designed to test the therapeutic efficacy of some hypotensive drugs and vegetable drinks on some biochemical indicators in male rabbits, where atherosclerosis was developed using 1% cholesterol with food. This study was conducted in June until the end of July 2017 in the Pharmacology Department/ General Company for Pharmaceutical Industry in Samarra. In the study, 50 local rabbits were randomly distributed by 10 groups each containing 5 animals. The first group considered as the control group. The second group is the control group treated with 1% cholesterol with the food, the third group treated with cholesterol (1% and captopril 0.71 mg), group 4 (cholesterol 1% with atenolol 0.71 mg / kg), group 5 (cholesterol 1%, amlodipine 0.07 mg / kg) , group 6 treated with cholesterol 1% and aldomet (0.57 mg / kg), group 7 (cholesterol 1% and furosemide at 3.5 mg / kg), group 8 (cholesterol 1% with garlic syrup 2 ml), group 9 treatment cholesterol 1% and lemon juice), and group 10 Treatment with (1% cholesterol and green tea syrup 2 ml). The results of the study showed a significant increase (P≤0.01)) at the level of each of cholesterol triple and triglycerides, proteins and low density lipoproteins, very low density lipoproteins, also led to obtain a significant decrease in the level of high-density lipoproteins (HDL) in the treatment group with cholesterol 1% compared to control group. At the time of the treatment of anti- pressure drugs: Captopril, Atenolol, Amlodipine ,Aldomet, and Furosmide , there were no significant differences in the cholesterol level of all pharmacological groups. Moral differences were not found in LDL-C and there was a significant decrease (P≤0.01) of the level of triglycerides, proteins and very low density lipoproteins, and there was a significant increase in the level of high-density lipoproteins HDL-C, while treatment with plant juices, there was a significant decrease (P≤0.01) in the level of total cholesterol and triglycerides and LDL, and VLDL, high-density lipoprotein (HDL-C) increased when treated with garlic, lemon and green tea. We conclude pressure drugs of any kind can cure atherosclerosis or prevent high fat, unlike its counterparts OF plants, which have shown a significant effect on controlling lipid profile and reducing their effects and future risks on the heart.

scholarly journals Dietary Sources of Fructose and Its Association with Fatty Liver in Mexican Young Adults

Nutrients ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 522 ◽  
Author(s):  
Alejandra Cantoral ◽  
Alejandra Contreras-Manzano ◽  
Lynda Luna-Villa ◽  
Carolina Batis ◽  
Ernesto Roldán-Valadez ◽  
...  
Keyword(s):  
Young Adults ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Liver Fat ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Sweetened Beverages ◽  
Fatty Liver Index ◽  
Hepatic Steatosis Index ◽  
Sectional Analysis

Fructose intake has been associated with non-alcoholic fatty liver disease (NAFLD). The objective of this study was to assess the consumption of dietary fructose according to: 1) classification of hepatic steatosis by two indexes and 2) diagnosis of NAFLD by MRI. We conducted a cross-sectional analysis among 100 young adults from Mexico City. The Hepatic Steatosis Index (HSI) and the Fatty Liver Index (FLI) were estimated using Body Mass Index (BMI), waist circumference, and fasting concentrations of glucose, triglycerides, and hepatic enzymes (ALT, AST, GGT). A semi-quantitative food frequency questionnaire was administered to obtain dietary sources of fructose. We estimated the concordance between the hepatic indices and NAFLD and the correlation between the index scores and the percentage of liver fat. Eighteen percent presented NAFLD; 44% and 46% were classified with hepatic steatosis according to HSI and FLI, respectively. We compared dietary intake of fructose by each outcome: HSI, FLI, and NAFLD. Sugar-sweetened beverages (SSB) and juices were consumed significantly more by those with steatosis by FLI and NAFLD suggesting that SSB intake is linked to metabolic alterations that predict the risk of having NAFLD at a young age.

scholarly journals STUDY OF THE EFFECT OF CHITOSAN EXTRACTED FROM THE MUSHROOM ON THE EXPERIMENTALLY INDUCED HYPERLIPIDEMIA IN MALE RABBITS

2021 ◽  
Vol 13 (2) ◽  
pp. 79-88
Author(s):  
إبراهيم خلف حميد الدليمي ◽  
◽  
أسماء هاشم شاكر ◽  
فهد خلف ياسين ◽  
◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Research Study ◽  
Low Density Lipoproteins ◽  
High Density Lipoproteins ◽  
Control Group ◽  
Low Density ◽  
Very Low Density Lipoproteins ◽  
Glucose Levels ◽  
Significant Difference ◽  
Therapeutic Evaluation

The present study aimed to identify the therapeutic evaluation of chitosan extracted from the fungus cushroom and pure chitosan on glucose and lipid profile in the blood of 35 male rabbits with hyperlipidemia induced experimentally by cholesterol. The tests included estimation of glucose levels, total cholesterol, triglycerides, high-density lipoproteins, low-density lipoproteins, and very low-density lipoproteins. hyperlipidemia was induced in the male rabbits used in the study which was administered orally with cholesterol 150mg/kg body weight for a week. rabbits were divided into seven groups: control, cholesterol, pure chitosan, mushroom chitosan, cholesterol and pure chitosan, cholesterol and mushroom chitosan and cholesterol and simvastatin. The results of the study showed, the hyperlipidemia induced experimentally resulted a significant increase (P<0.05) in TC, TG, LDL, and VLDL, while no significant difference in HDL compared with control group, on the otherwise the glucose level significantly increase than control. Also, groups of animals treatment with pure chitosan and mushroom chitosan showed a significant decrease (P<0.05) in glucose, TC, TG, LDL, and VLDL, and no significant difference in HDL compared with control group. While, the groups showed treatment with cholesterol and pure chitosan, cholesterol and mushroom chitosan, cholesterol and simvastatin a significant decrease (P<0.05) in glucose, TC, TG, LDL, and VLDL, and a significant increase (P<0.05) in HDL compared with the cholesterol group. The research study revealed that chitosan extracted from mushroom can control the levels of fat concentrations and their complications, in addition to its important role in biochemical variables, and treatment of most disease cases, especially cardiovascular disease.

Sign in / Sign up

Export Citation Format

Share Document